Author:
Sánchez-Muñoz Alfonso,Pérez-Ruiz Elisabeth,Jiménez Begoña,Ribelles Nuria,Márquez Antonia,García-Ríos Isabel,Alba Conejo Emilio
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference48 articles.
1. Ferlay J, Bray F, Pisani O, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, Version 2.0. IARC Cancer Base, No. 5
2. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogen in human breast and ovarian cancer. Science 244:707–712
3. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl Med 344:783–792
4. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor 2-positive metastatic breast cancer administered as first line treatment: the M77001 study group. J Clin Oncol 23:4265–4274
5. Vogel CL, Burris HA, Limentani S et al (2009) A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. Program and abstracts of the 2009 Annual Meeting of the American Society of Clinical Oncology, May 29–June 2, Orlando, FL. Abstract 1017
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献